We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.8B
AUM Growth
-$577M
Cap. Flow
-$347M
Cap. Flow %
-3.21%
Top 10 Hldgs %
77.46%
Holding
139
New
12
Increased
27
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$517M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$232M
3
DBVT
DBV Technologies
DBVT
+$142M
4
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$66.6M
5
NGNE icon
Neurogene
NGNE
+$63.9M

Top Sells

Rank Stock Value
1
XOMA
Xoma
XOMA
+$57M
2
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$29.2M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.1M
4
OMER icon
Omeros
OMER
+$9.78M
5
DYAX
DYAX CORPORATION
DYAX
+$8.72M

Sector Composition

Rank Sector Weight
1 Healthcare 74.03%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
101
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.44M 0.01%
35,649
– –
CLLS
102
Cellectis
CLLS
$289M
$1.32M 0.01%
50,000
– –
TENX icon
103
Tenax Therapeutics
TENX
$401M
$1.26M 0.01%
13
+2
+18% +$229K
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$1.2M 0.01%
100,000
– –
BDSI
105
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.17M 0.01%
210,021
– –
ABUS icon
106
Arbutus Biopharma
ABUS
$849M
$1.1M 0.01%
180,582
– –
WINT
107
DELISTED
Windtree Therapeutics Inc
WINT
$1.07M 0.01%
254,975
– –
NBSE
108
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.02M 0.01%
926
– –
ALNY icon
109
Alnylam Pharmaceuticals
ALNY
$38.2B
$911K 0.01%
11,340
– –
ALDX icon
110
Aldeyra Therapeutics
ALDX
$95.3M
$828K 0.01%
142,000
– –
TRIL
111
DELISTED
Trillium Therapeutics Inc.
TRIL
$821K 0.01%
+63,014
New +$1.16M
AIXC
112
AIxCrypto Holdings Inc
AIXC
$13.4M
$820K 0.01%
3
– –
XLRN
113
DELISTED
Acceleron Pharma
XLRN
$716K 0.01%
28,765
– –
QURE icon
114
uniQure
QURE
$2.79B
$614K 0.01%
30,000
– –
AKAO
115
DELISTED
Achaogen Inc
AKAO
$576K 0.01%
100,000
– –
FMI
116
DELISTED
Foundation Medicine, Inc.
FMI
$385K ﹤0.01%
20,892
– –
SGYP
117
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$356K ﹤0.01%
+67,100
New +$519K
CCXI
118
DELISTED
ChemoCentryx, Inc.
CCXI
$297K ﹤0.01%
49,064
– –
FPRX
119
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$296K ﹤0.01%
19,247
– –
APTO
120
DELISTED
Aptose Biosciences, Inc.
APTO
$144K ﹤0.01%
74
– –
BTX.WS
121
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$17K ﹤0.01%
20,084
– –
TCRT icon
122
Alaunos Therapeutics
TCRT
$4.69M
– –
-1,262
Closed -$2.27M
VNDA icon
123
Vanda Pharmaceuticals
VNDA
$298M
– –
-409,881
Closed -$5.2M
VXRT
124
DELISTED
Vaxart
VXRT
– –
-75,495
Closed -$1.72M
XOMA
125
DELISTED
Xoma
XOMA
– –
-734,176
Closed -$57M
2 3 4
5
6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2015 Portfolio in Review

As of Q3 2015, Baker Bros. Advisors held 139 positions worth $10.8B, down 5.1% from $11.4B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $347M in Q3 2015, closing 6 positions and reducing 8 holdings. Its most notable exit was Xoma, an estimated $57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 72% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in MEDIVATION, INC. worth $28M.

  • Baker Bros. Advisors's largest Q3 2015 buy was MEDIVATION, INC.: 659,752 shares worth $28M.
  • Baker Bros. Advisors added most to Incyte in Q3 2015, an estimated $517M increase.
  • Baker Bros. Advisors's biggest Q3 2015 reduction was Alder Biopharmaceuticals, cutting an estimated $16.1M.
  • Baker Bros. Advisors fully exited Xoma in Q3 2015, selling an estimated $57M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $10.8B portfolio in Q3 2015.
  • Baker Bros. Advisors opened 12 new positions and closed 6 in Q3 2015.
  • Baker Bros. Advisors's portfolio value fell 5.1% quarter-over-quarter to $10.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.